How do you rank and score these providers?

Each provider is evaluated across six weighted dimensions: Value (25%), Effectiveness (25%), User Experience (15%), Trust & Safety (15%), Accessibility (10%), and Support (10%). We research publicly available information, user reviews, clinical evidence, and pricing data, then compute a weighted overall score out of 10.

Are your rankings independent?

Our editorial rankings and scores are determined independently of commercial relationships. Some providers on this page may have affiliate agreements with us — meaning we earn a commission if you click through and make a purchase — but this does not influence rankings. Sponsored placements are clearly labeled.

How often are the rankings updated?

Rankings are reviewed and updated on a rolling basis as pricing, availability, and clinical evidence changes. The 'Updated' badge at the top of the page reflects the most recent review date.

Best Direct Primary Care GLP-1 Providers in 2026 — Ranked & Reviewed

Direct Primary Care (DPC) is a membership-based primary-care model that strips out insurance billing and replaces it with a flat monthly fee. A small but growing group of DPC practices have added GLP-1 weight-loss medication to the membership at wholesale or near-wholesale cost — fundamentally different from the DTC marketplace pattern where you pay $300-$500/month for the medication and have no continuous primary-care relationship. The DPC model integrates lab monitoring, medication adjustments, and side-effect management within an ongoing provider relationship, which most clinicians consider the gold standard for chronic-weight-management care. Membership fees typically run $50-$150/month; wholesale GLP-1 then runs $65-$300/month depending on drug, dose, and form. For patients without insurance coverage of brand-name Wegovy/Zepbound, DPC can be the lowest total-cost path to GLP-1 plus comprehensive care.

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

How we rank & what counts as “legit”

Every provider in this ranking is scored against our published six-factor rubric^[1] — value, effectiveness, user experience, trust & safety, accessibility, and support.

Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro are separately FDA-approved under their own NDA numbers^[4]^[5]. Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial^[6], and for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) from SURMOUNT-1^[7]; the SURMOUNT-5 head-to-head published in 2025 compared the two directly^[8].

Insurance coverage for anti-obesity medications varies widely by state Medicaid program and commercial plan^[9]^[10]. Compounded and brand-name GLP-1s are generally FSA/HSA eligible with a prescription under IRS Publication 502^[11].

Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

Quick Picks: Top 1

#	Provider	Score	Best For	From
1	Primary Clinic (Direct GLP)	8.0	Patients in the 10 covered states who want GLP-1 medications as part of a continuous Direct Primary Care relationship (including labs, routine meds, unlimited visits, and ongoing provider monitoring) rather than a transactional DTC marketplace purchase, and who calculate the $89/mo membership fee plus wholesale med cost is favorable vs $300-$500/mo all-in DTC pricing.	$65/mo	Visit

Detailed Reviews

Primary Clinic (Direct GLP)

Best for: Patients in the 10 covered states who want GLP-1 medications as part of a continuous Direct Primary Care relationship (including labs, routine meds, unlimited visits, and ongoing provider monitoring) rather than a transactional DTC marketplace purchase, and who calculate the $89/mo membership fee plus wholesale med cost is favorable vs $300-$500/mo all-in DTC pricing.

8.0

Primary Clinic (directglp1.com, also branded as Direct GLP) is a Direct Primary Care (DPC) telehealth membership model — fundamentally different from the DTC GLP-1 marketplace pattern that dominates the rest of the WLR directory. Members pay $89/month for unlimited primary care, direct text access to a provider, same-day virtual visits, routine labs included, and 'thousands of medications' covered. GLP-1 medications are then offered AT WHOLESALE COST to active members with no markup: compounded 503A tirzepatide ranges $110/mo at 2.5mg to $235/mo at 10mg; compounded 503A semaglutide ranges $65/mo at 0.25-0.5mg to $160/mo at 2.7mg. The DPC model means GLP-1 access is bundled with ongoing lab monitoring, medication adjustments, and side-effect management within a continuous primary care relationship. Currently serves 10 states: WA, NM, AZ, UT, FL, DC, KS, OK, VA, GA. Pharmacy partners are described as 'licensed 503A pharmacies' but not named specifically. LegitScript certification is not mentioned. Verbatim disclosure: 'These compounded products are not affiliated with or approved as generic versions of brand-name GLP-1 medications.' Live-verified 2026-05-19 via Chrome MCP (homepage is JavaScript-rendered SPA).

Score Breakdown

Value25%

Effectiveness25%

User Experience15%

Trust & Safety15%

Accessibility10%

Support10%

Pros

✓Direct Primary Care (DPC) model integrates GLP-1 with continuous primary care — fundamentally different from DTC marketplace pattern
✓GLP-1 medications at WHOLESALE COST with no markup — semaglutide from $65/mo, tirzepatide from $110/mo (members only)
✓Unlimited primary care visits + direct text access + same-day care all bundled in $89/mo membership
✓Routine labs and thousands of medications included in membership (no surprise bills)
✓Per-dose pricing transparency for both semaglutide and tirzepatide (all 8 dose tiers listed publicly)
✓Verbatim 503A compounded-medication disclaimer published (no FDA-approval/brand-name confusion)
✓Hybrid model addresses common DTC complaint of 'no continuity of care' for GLP-1 patients

Cons

✗10 states only (WA/NM/AZ/UT/FL/DC/KS/OK/VA/GA) — limited national coverage vs 50-state DTC platforms
✗Membership required to access wholesale GLP-1 pricing — $89/mo adds to year-1 cost (~$1,068/yr fixed)
✗Specific 503A pharmacy partners NOT named
✗LegitScript certification NOT mentioned on the site
✗Named medical director NOT disclosed
✗Corporate legal entity (LLC/Inc/PC) NOT disclosed
✗Brand-name Wegovy/Ozempic/Mounjaro/Zepbound NOT offered — compounded only
✗Site is fully JavaScript-rendered — limited HTML-only crawler visibility
✗Refund policy NOT publicly disclosed

Starting from $65/mo

Visit Primary Clinic (Direct GLP) →

Frequently Asked Questions

Sources & methodology — as of May 2026

1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.